NCT03778138View on ClinicalTrials.gov

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC

PHASE2UnknownINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
Non-squamous Cell Non-Small Cell Lung Cancer
Interventions
DRUG

Anlotinib plus Pemetrexed

Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)

Trial Locations (1)

450000

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Henan Provincial People's Hospital

OTHER